LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
Podcast: The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Pipeline
Deals
Financings
Earnings Summary
Stock Summary
Articles
Vtv Therapeutics Inc.
Headquarters:
High Point, NC, United States of America
Website:
http://vtvtherapeutics.com
Year Founded:
1999
Status:
Public
Industry Sector:
HealthTechnology
CEO:
Paul Jai Sekhri
Number Of Employees:
23
Enterprise Value:
$45,215,726
PE Ratio:
-6.02
Exchange/Ticker 1:
NASDAQ:VTVT
Exchange/Ticker 2:
N/A
Latest Market Cap:
$53,681,900
BioCentury
|
Oct 4, 2024
Management Tracks
Resolution names Paul Sekhri chair
Plus: Dadswell leaving Illumina as general counsel and updates from Eliem, Codexis, Oculis, Illumina, Eupraxia and PharmaJet
Read More
BioCentury
|
Oct 3, 2024
Finance
Kurma investing new fund; Kailera advancing obesity assets with $400M
BioCentury’s latest Venture Report also features news about LoQus23, Aktis, Resolution, Triveni, Flagship and more
Read More
BioCentury
|
Mar 1, 2024
Finance
Public equity report: PIPEs, follow-ons for 11 biotechs add up to $3B+
Viking, Celldex, Janux offerings top list of follow-ons; Denali, Crinetics, Avidity among those raising PIPEs
Read More
BioCentury
|
Jan 5, 2024
Distillery Therapeutics
BACH1 inhibition for tuberculosis
Read More
BioCentury
|
Dec 6, 2023
Data Byte
After Carmot deal, seven clinical oral GLP-1s remain unpartnered
A look at the oral GLP-1 pipeline
Read More
BioCentury
|
Nov 3, 2023
Management Tracks
Prokarium hires Henry as COO
Plus: Actinium hires Bodarky and updates from Summit, CentiVax, vTv and Calidi
Read More
BioCentury
|
Jun 27, 2023
Management Tracks
Kramer retires from Emergent
Plus: Zimmermann named CBO at SonoThera and updates from Secretome, Healthcare, Ultima and Koneska
Read More
BioCentury
|
Dec 15, 2022
Management Tracks
Debra Yu leaving LianBio
Plus: Bayer vet Weinand appointed chair at Umoja, and updates from vTv, Gradalis, Generate and more
Read More
BioCentury
|
Jul 28, 2022
Management Tracks
CEO Li Yi resigns from Sino
Plus Sekhri becomes CEO of vTv and updates from Eisai, Summit and more
Read More
BioCentury
|
Mar 5, 2022
Management Tracks
Entos builds out team with Chen as CMO, Ding as CBO
Plus Henderson becomes CEO of Wren, and updates from Bolt, argenx and more
Read More
Items per page:
10
1 - 10 of 39
Help Center
Username
Request Training
Submit Data Correction
Ask a Question
Elevio by Dixa
Help